Jan 08, 2024 / 10:15PM GMT
Rachel Marie Vatnsdal Olson - JPMorgan Chase & Co, Research Division - Analyst
Hello everyone. This is Rachel Vatnsdal with the life science tools and diagnostics team here at JPMorgan. I'm pleased to introduce the Catalent management team. As we typically have done with most of these sessions, this will be a roughly 20-minute presentation followed by 20 minutes of Q&A. And with that, I will hand it off to Alessandro.
Alessandro Maselli - Catalent, Inc. - President, CEO & Director
Thank you. Hello, everyone. Good afternoon. Welcome to our presentation. I'm very excited to be here. And before I get started, I want to share a short story yesterday when I stepped into the conference, I had one of those flashbacks, thinking about being here 12 months ago, 12 months -- the last 12 months and this flashback of what happened in the last 12 months and was quite a lot, right?
It was surely an eventful period for the industry event for Catalent but one in which we also made several progresses and we had also some exciting stuff happening. So hopefully
Catalent Inc at JPMorgan Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot